过去 90 天内没有内部人买入。最近一笔由 Zerbe Horst G 披露于 2022年10月03日。
IntelGenx Technologies Corp.：高管交易动态
IntelGenx Technologies Corp.属于医疗与制药行业。其高管的申报经由SEC (Form 4)发布。十二个月来，IntelGenx Technologies Corp.的高管没有新的申报，最新记录停留在2023年4月19日。
回溯至覆盖起点2006年，高管共申报102笔买入和25笔卖出。
本摘要仅基于SEC (Form 4)的披露信息，不预示股价未来走向。
该评分只在所属市场内对买入进行排名。仅在经过回测的策略范围内的交易所提供建议仓位；其他市场的信号仍处于观察状态。并非投资建议。
财务数据
财年 2023财年截至 2023年12月 · cache
- 股票TSXSEDI:4117795
- 14,000 股@ US$0.12473.1% 占其流量股票SEC:0001062993-22-020119:1标准退出：2022年12月29日 (T+90)
- 5,000 股@ US$0.128100.0% 占其流量股票SEC:0001062993-22-020119:0标准退出：2022年12月29日 (T+90)
- 5,000 股@ US$0.1243.3% 占其流量股票SEC:0001062993-22-020113:0标准退出：2022年12月28日 (T+90)
- 9,000 股@ US$0.1351.4% 占其流量股票SEC:0001062993-22-020022:1标准退出：2022年12月27日 (T+90)
- 1,000 股@ US$0.1310.7% 占其流量股票SEC:0001062993-22-020022:0标准退出：2022年12月26日 (T+90)
- 9,000 股@ CA$0.185股票TSXSEDI:4008315标准退出：2022年12月27日 (T+90)
- 1,000 股@ CA$0.18股票TSXSEDI:4008314标准退出：2022年12月26日 (T+90)
- 19,000 股@ US$0.13543.5% 占其流量股票SEC:0001062993-22-019976:0标准退出：2022年12月25日 (T+90)
- 19,000 股@ CA$0.185股票TSXSEDI:4007690标准退出：2022年12月25日 (T+90)
- 2,000 股@ US$0.1482.0% 占其流量股票SEC:0001062993-22-019908:1标准退出：2022年12月21日 (T+90)
- 8,000 股@ US$0.1477.9% 占其流量股票SEC:0001062993-22-019908:2标准退出：2022年12月22日 (T+90)
- 23,500 股@ US$0.14556.5% 占其流量股票SEC:0001062993-22-019908:0标准退出：2022年12月21日 (T+90)
- 25,000 股@ CA$0.185股票TSXSEDI:4005997标准退出：2022年12月20日 (T+90)
- 20,000 股@ CA$0.18股票TSXSEDI:4005993标准退出：2022年12月20日 (T+90)
- 25,000 股@ US$0.13826.2% 占其流量股票SEC:0001062993-22-019838:0标准退出：2022年12月20日 (T+90)
- 20,000 股@ US$0.13414.4% 占其流量股票SEC:0001062993-22-019862:0标准退出：2022年12月20日 (T+90)
- 10,526 股@ US$0.2963.5% 占其流量股票SEC:0001062993-22-016168:1
- 2,105 股@ US$0.2960.7% 占其流量股票SEC:0001062993-22-016170:1
- 71,123 股@ US$0.2281.5% 占其流量股票SEC:0001062993-22-016170:0
- 355,618 股@ US$0.22100.0% 占其流量股票SEC:0001062993-22-016168:0
- 10,526 股@ CA$0.38股票TSXSEDI:3975995
- 2,105 股@ CA$0.38股票TSXSEDI:3976000
- 355,618 股@ CA$0.2812股票TSXSEDI:3975992
- 71,123 股@ CA$0.2812股票TSXSEDI:3975999
171 条申报中的 25 条
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp. is a specialty pharmaceutical and drug-delivery company listed in the United States on the NASDAQ market. Although it is followed by U.S. investors and trades as a U.S.-listed equity, the company’s operating roots are Canadian: it was founded in 2003, later reorganized in 2006, and is headquartered in Montreal, Quebec, Canada. That dual profile matters for investors, because IntelGenx is a small-cap biotech/pharma name whose valuation is driven less by scale and more by intellectual property, development milestones, partner traction, and manufacturing execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
The company’s core activity is the development and contract manufacturing of novel oral drug-delivery products, especially oral thin films designed for rapid dissolution or controlled release. In practice, IntelGenx operates as a specialized CDMO-like platform: it offers pharmaceutical R&D, regulatory support, technology transfer, manufacturing scale-up, and commercial production services to partners. This business model can create multiple monetization paths—service fees, manufacturing revenues, and potentially royalties—if a program progresses successfully through development and into launch. Its proprietary technology set includes VersaFilm™, DisinteQ™, and VetaFilm™, with the latter aimed at veterinary applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
展开全文收起
From a competitive standpoint, IntelGenx occupies a niche position. It is not a large-cap pharmaceutical manufacturer; rather, it competes as a technology-driven formulation specialist. Its edge depends on proving that its oral-film and related delivery platforms can offer practical patient benefits, scalable manufacturing, and attractive partner economics. For investors, that means the company should be assessed as a platform business: success is tied to licensing, partnering, and the commercialization of programs, not to a broad commercial drug portfolio. The company has also explored adjacent markets such as non-prescription cannabis-infused oral films in Canada and psychedelic-related opportunities through strategic partnerships, showing an effort to broaden the applicability of its delivery expertise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
Geographically, IntelGenx is Canadian in operations but U.S.-oriented in market visibility because of its NASDAQ listing in the United States. That mix is common among development-stage healthcare companies seeking access to deeper U.S. capital markets while retaining a Canadian operating base. The company’s headquarters in Montreal also anchors its manufacturing and development footprint, which is relevant when evaluating operating costs, regulatory oversight, and cross-border execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299323008012/form10k.htm?utm_source=openai))
Recent developments point to a company still in transition. SEC filings and related disclosures reference loan amendments, strategic financing arrangements, and ongoing relationships involving atai Life Sciences. The record also reflects restructuring-related activity around IntelGenx’s operating assets in 2024–2025, underscoring that the story is as much about balance-sheet management as it is about technology development. In short, IntelGenx remains a high-risk, high-optional-value specialty pharma platform: attractive for investors who understand early-stage execution risk, but still dependent on funding, partnerships, and successful commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1098880/000106299324006905/form10k.htm?utm_source=openai))
